Next-Gen Immuno-Oncology Congress - Virtual Event (Time Zone - ET)

Monoclonal Antibody & Cellular Therapy

Registration

Opening remark by Chairperson

Immunotherapy in 2020: Beyond checkpoint inhibition and CAR T cell

Geert Mudde, CSO and Managing Director, Founder, OncoQR ML GmbH, S-TARget therapeutics

Panel Discussion: The promises of CAR-T cell therapy in 2020 and beyond

Targeting AXL to leverage checkpoint immunotherapy: Updated results of the BGBC008 phase II study of bemcentinib and pembrolizumab in recurrent NSCLC

Hani Gabra , Chief Medical Officer , BerGenBio

Mechanisms of Resistance and Response to anti-CD19 CAR T cell Therapy in LC

John Rossi, Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Targeting Bispecific Antibodies and Developing Systems Disease Models in I/O

John M. Burke, President, CEO, and Co-founder  , Applied BioMath

REGN4018, a Mucin 16 bispecific T cell engaging antibody for the treatment of ovarian cancer

Alison Crawford, Associate Director of Immuno-oncology, Regeneron Pharmaceuticals, Inc.

Antibodies & CAR-T Cellular Therapy

Laboratory Considerations for Immuno-Oncology Clinical Trials - Q2 Solutions

New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

Eric Halioua, President & CEO, PDC*line Pharma

Deciphering the function of B cells in human cancer

Tullia Bruno, Assistant Professor, Immunology, University of Pittsburgh

Closing remark by chairman

Networking│One-to-One Networking Meetings

End of Day 1

Advancing Precision Medicine: Emerging Therapeutic and Technological Approaches

Registration

Opening remark by Chairperson

Are there still unmet needs in ICI therapy?

Stefan Glueck, Ex- Vice President, Global Head Franchise Oncology, Regeneron

Cannabinoids as companion treatments for cancer

Philip Arlen, Chief Scientific Officer, Senior Vice President, Diverse Biotech

Solution Provider Presentation - Biocytogen

Solution Provider Presentation - Proteome Sciences

FDA Accelerated Approval Pathways for Cell and Gene Therapy 

A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer 

Indu Venugopal , Research Scientist, SRI International

Cancer Vaccines & Biomarkers

Solution Provider Presentation - PromoCell GmbH

First-in-class biotherapeutics, designed to “heat up” cold tumor microenvironment for combination therapy with PD(L)1 inhibitors

Christie Zhang , Project Team Leader, Elstar Therapeutics

Oncolytic Viruses: NOTCHing up the game

Balveen Kaur, Professor, The University of Texas Health Science Center

Closing remark by chairman

Networking│One-to-One Networking Meetings

End of Day 1

Therapeutics antibodies & TCR-based Cellular Therapy

Registrations

Opening remark by Chairperson

PD-1 Antibodies are Transforming Cancer Care

Development of a Next Generation Anti-Cancer Immunotherapy: A Humanized anti-BTN3A Antibody that Activates Gamma-Delta (Vg9-Vd2) T Cells

Alem Truneh, Co-founder & Chief Technology Officer, ImCheck Therapeutics

Novel serum-free and xeno-free T cell medium for improved T cell therapy manufacturing

Solution Provider Presentation - PhenoSwitch Bioscience Inc.

Completing the immune cycle by targeting novel macrophage checkpoints

Tatiana Novobrantseva, Co-founder and Chief Scientific Officer, Verseau Therapeutics

Solution Provider Presentation - PHC Corporation

Unleashing the Power of SQZ’d Cells to Engineer a New Generation of Cancer Vaccines

Katherine Seidl, Vice President Immunology Research and Development, SQZ Biotechnologies

Closing remarks from Chairman

Networking│One-to-One Networking Meetings

End of Conference

Registrations

Opening remark by Chairperson

Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy 

Nuzhat Pathan, Director, Early Development, Translational and Immuno-Oncology, Pfizer

Cancer Immunotherapy: A Targeted, Personalized and Off-the-Shelf Approach

William Williams, President, CEO, Briacell Therapeutics Corporation

Cancer Immunotherapy: accelerating preclinical drug candidate selection using the full advanced human immune system mouse models

Bradlee Heckmann, CSO, Asha Therapeutics

Unleashing the power of NGS to unlock the secrets of immuno-oncology 

Raed Samara Ph.D , Associate Director, Global Product Management, NGS , QIAGEN

Preventing drug resistance to targeted therapeutics in ER+HER2- Breast Cancer

Nathaniel Wang, Oncology Vaccines Project Leader, Janssen, Pharmaceutical Companies of Johnson and Johnson

Preclinical modeling of immune responses to Cancer: improving translatability of bench-side discoveries to clinical outcomes

Mithun Khattar, Immuno-Oncology Lead, Takeda Oncology

It’s time to look beyond Checkpoint Blockade

Shailesh Dudhgaonkar , Deputy Research Director , Biocon Bristol Myers Squibb R&D Center (BBRC)

Closing remarks from Chairman

Networking│One-to-One Networking Meetings

End of Conference